Thrombosis, a key factor in most cardiovascular diseases,
is a
major contributor to human mortality. Existing antithrombotic agents
carry a risk of bleeding. Consequently, there is a keen interest in
discovering innovative antithrombotic agents that can prevent thrombosis
without negatively impacting hemostasis. Platelets play crucial roles
in both hemostasis and thrombosis. We have previously characterized
calcium- and integrin-binding protein 1 (CIB1) as a key regulatory
molecule that regulates platelet function. CIB1 interacts with several
platelet proteins including integrin αIIbβ3, the major glycoprotein receptor for fibrinogen on platelets.
Given that CIB1 regulates platelet function through its interaction
with αIIbβ3, we developed a fluorescence
polarization (FP) assay to screen for potential inhibitors. The assay
was miniaturized to 1536-well and screened in quantitative high-throughput
screening (qHTS) format against a diverse compound library of 14,782
compounds. After validation and selectivity testing using the FP assay,
we identified 19 candidate inhibitors and validated them using an
in-gel binding assay that monitors the interaction of CIB1 with αIIb cytoplasmic tail peptide, followed by testing of top hits
by intrinsic tryptophan fluorescence (ITF) and microscale thermophoresis
(MST) to ascertain their interaction with CIB1. Two of the validated
hits shared similar chemical structures, suggesting a common mechanism
of action. Docking studies further revealed promising interactions
within the hydrophobic binding pocket of the target protein, particularly
forming key hydrogen bonds with Ser180. The compounds exhibited a
potent antiplatelet activity based on their inhibition of thrombin-induced
human platelet aggregation, thus indicating that disruptors of the
CIB1- αIIbβ3 interaction could carry
a translational potential as antithrombotic agents.